Corresponding Author: Avery H. Weiss, MD, Division of Ophthalmology, OA.9.220, Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA 98105.
Neuro Oncol. 2013 Nov;15(11):1560-7. doi: 10.1093/neuonc/not120. Epub 2013 Oct 6.
We wanted to determine the sensitivity and specificity of serial changes in visual acuity and visual evoked potentials (VEPs) to detect radiological progression of tumor volume in children with optic pathway gliomas.
From a retrospective review of a cohort of 69 patients, 54 patients met inclusion criteria (31 with primary chemotherapy, 4 with primary radiotherapy, and 19 with stable tumor volume and no treatment). Age at presentation ranged from 0.3 to 13 years. Patients were serially followed by MRI, age-corrected visual acuity in log minimum angle of resolution (logMAR), and pattern VEP. Longitudinal data averaged 7.9 years (range 0.5-16 y). Visual assessments were aligned with MRI data within 6-month intervals. Tumor progression was defined by 25% or greater increase in volume.
Visual acuity in the better eye had poor sensitivity and specificity for detecting tumor volume progression (0.5 and 0.5, respectively). Visual acuity in the worse eye showed worse sensitivity and specificity because false positives (visual decline without tumor progression) were more frequent than true positives (visual decline with tumor progression). VEPs showed slightly better sensitivity and specificity (0.69 and 0.58, respectively). In patients with stable tumors, visual acuity fluctuated ±0.55 logMAR (SD = 0.15) between examinations. VEP amplitude fluctuated -0.74 to 0.48 log units (SD = 0.19) between examinations.
Serial changes in visual function do not reliably detect tumor progression. Conversely, tumor progression does not reliably indicate decreased visual function. Objective visual function and serial MRIs are complementary in management of optic pathway gliomas.
我们旨在确定视力和视觉诱发电位(VEPs)的连续变化的灵敏度和特异性,以检测视神经胶质瘤患儿肿瘤体积的放射学进展。
从 69 例患者的回顾性队列中,54 例符合纳入标准(31 例接受初始化疗,4 例接受初始放疗,19 例肿瘤体积稳定且未治疗)。发病时的年龄范围为 0.3 至 13 岁。患者通过 MRI、年龄校正后的最小分辨角对数视力(logMAR)和图形 VEP 进行连续随访。纵向数据平均为 7.9 年(范围 0.5-16 年)。视觉评估与 MRI 数据在 6 个月的间隔内对齐。肿瘤进展定义为体积增加 25%或以上。
较好眼的视力对检测肿瘤体积进展的敏感性和特异性均较差(分别为 0.5 和 0.5)。较差眼的视力显示出较差的敏感性和特异性,因为假阳性(无肿瘤进展的视力下降)比真阳性(肿瘤进展时的视力下降)更为频繁。VEPs 显示出略高的敏感性和特异性(分别为 0.69 和 0.58)。在稳定肿瘤的患者中,视力在检查之间波动±0.55 logMAR(SD=0.15)。VEP 幅度在检查之间波动-0.74 至 0.48 log 单位(SD=0.19)。
视觉功能的连续变化不能可靠地检测肿瘤进展。相反,肿瘤进展并不一定表明视力下降。客观视觉功能和连续 MRI 在视神经胶质瘤的治疗中是互补的。